Objective: Inflammatory cytokines may influence both labile anger and depression. Both psychiatric conditions can occur during interferon alfaYbased treatments. Evidence also indicates a central nervous system role for tumor necrosis factor > (TNF->), whose expression may be increased by interferon alfa. A polymorphism in the promoter region of TNF-> has been associated with various inflammatory illnesses. We therefore hypothesized that this TNF-> polymorphism would influence susceptibility to psychiatric symptoms during interferon alfa therapy.
I nflammation may be involved in the etiology of mood disorders. 1 Genetic polymorphisms in the inflammatory system have been associated with major depressive disorder (MDD), 2 and twins concordant for MDD have elevated levels of inflammatory activity. 3 In addition, inflammatory cytokines are implicated in the neurobiology of aggression, 4 and mice bred for high aggression have an elevated proinflammatory response. 5 Elevated production of tumor necrosis factor > (TNF->) has been associated with hostility in humans. 6Y8 BAnger attacks[ have been described during MDD 9 and various other psychiatric diagnoses. 10 Abnormal regulation of anger, with both genetic and neurobiologic influences, can be related to significant violence. 11, 12 Labile anger can be measured by inquiring about having loss of control over switches in temper; sudden angry feelings with the urge to yell; or feeling so mad as to experience shaking, a pounding heart, and/or the urge to hit.
Consistent with a possible relationship between anger dysregulation and inflammatory cytokines, labile anger and hostility have been observed during exogenous interferon alfa therapy. 13Y20 During treatment with interferon alfa, between 15% and 40% of patients also develop MDD. 21 However, worsened labile anger may be distinct from MDD. 22, 23 Interferon alfaYbased therapies are the primary recommendation for chronic hepatitis C, 20, 24 which affects more than 170 million people and results in approximately 10,000 deaths per year in the USA. 25, 26 Importantly, not everyone exposed to elevated inflammatory cytokines such as interferon alfa develops worsened labile anger or MDD.
Genetic variation in the serotonergic system may be a source of resilience to developing MDD. 27Y29 Less is known about resilience or vulnerability for developing worsened labile anger. However, genetic variation in TNF-> may be a plausible influence. Tumor necrosis factor > is biologically active in the brain and can influence synaptic strength, 30 ion channels, 31 synaptic scaling, 32 neurogenesis, 33 and serotonin transporter function. 34 It is produced throughout the limbic and hypothalamic regions, where it can be influenced by peripheral inflammatory cytokines. 35Y39 Tumor necrosis factor > can mediate the induction of indolamine deoxygenase and depressionlike behaviors after peripheral inflammation. 40 Peripherally administered TNF-> can affect both neurotransmitter and endocrine release. 41, 42 In humans, anti-TNF-> therapy may alleviate some mood-related symptoms. 43Y45 The BA[ allele in a promoter region of the TNF-> gene (A-308G) has been associated with higher TNF-> plasma levels, 46Y48 arthritis, 49,50 acquired immunodeficiency syndromeYassociated dementia, 51 Parkinson disease, 52 Alzheimer disease, 53 asthma, 54Y56 and metabolic syndrome. 57 In elderly patients, the A allele is associated with cognitive dysfunction. 58 To date, however, evidence for an association between the A allele and mood disorders is equivocal. Small studies suggest an association. 59Y61 Conversely, others report no association with MDD but a possible protective association with bipolar II disorder. 62 Several larger studies have found no association with childhood mood disorder 63Y65 or with postpartum mood disorder. 66 Whether it is associated with risk for labile anger has not been examined. Therefore, in subjects with elevated states of peripheral inflammation as a result of interferon alfa administration, we prospectively examined the association of this candidate polymorphism with the development of either labile anger or depression.
MATERIALS AND METHODS
We followed up subjects given interferon alfa as described previously 28, 67 and as approved by the University of Pittsburgh Institutional Review Board. In brief, patients with chronic hepatitis C (n = 105) who were initiating pegylated interferon alfa-2a (135 mg/wk) or interferon alfa-2b (120 or 150 mg/wk) and oral ribavirin treatment were examined before treatment and then for 16 weeks during therapy. 68Y72 Patients were excluded from these analyses if they had active mood, anxiety, psychotic, and drug/alcohol use disorders within 6 months before starting interferon alfa. As antidepressants can affect mood, labile anger, 73 and/or cytokine levels, 74 data from individuals on antidepressants were excluded.
Major depressive disorder during interferon alfa treatment was diagnosed using the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Axis I disorders. 75 The 21-item Beck Depression Inventory (BDI) II was used to assess depressive symptoms at week 2 and during monthly visits (but could be returned by mail if the participant was unable to attend the scheduled appointment). 76 The Anger Irritability and Assault Questionnaire, a 28-item selfreport, 77 was similarly used to prospectively assess labile anger. Items on this questionnaire are scored 0 to 3, with subscales that include labile anger (range, 0Y18), irritability, and assault.
Monthly plasma samples were used for enzyme-linked immunosorbent assays to determine TNF-> levels (Alpco, Salem, NH; sensitivity, 1.56 pg/mL) and were run in duplicate. Genomic DNA was isolated from lymphocytes using the Pure-Gene kit (Gentra Systems, Minneapolis, Minn) or from whole blood using the QuickGene-Mini80 kit (Fujifilm Life Science; Holliston, Mass, www.autogen.com). A-308G (rs1800629) was genotyped by the 5 ¶-nuclease (TaqMan) assay using the ABI 7900 DNA detection system, using Assays-on-Demand and Assaysby-Design (Applied Biosystems, Inc, Foster City, Calif). The uncommon A/A genotype was combined with the A/G heterozygotes for statistical analyses. The serotonin transporter promoter length polymorphism (5-HTTLPR) was assessed as previously described. 28 All statistics used SPSS 17.0. (SPSS Inc, Chicago, Ill) Skewed TNF-> levels were corrected using a square root transformation. Repeated-measure mixed-effect analyses with an antedependence covariance structure 78 were used to compare changes in either subjective symptoms over time (ie, assessing an interaction between genotype and time). We confirmed the appropriate choice of covariance structure, as the antedependence model produced the smallest j2 log likelihood (data not shown). Kaplan-Meier survival analyses examining time until MDD development were compared using the Mantel-Cox log-rank test. Results are presented as mean (SD), unless otherwise indicated.
RESULTS
Participants were 67% men, 90% European American, 47 (11) years (range, 18Y72 years), and 87 (17) kg (range, 46Y144 kg) and 44% had any prior history of mood disorder and 34% had any prior history of drug/alcohol use disorder. Demographics did not differ between those who developed MDD and those who did not (Table 1 ) nor did brand of interferon alfa or dose of ribavirin. The TNF-> polymorphism was in Hardy-Weinberg equilibrium with 4 A/A, 29 A/G, and 72 G/G. The A allele was more prevalent in African Americans (t 103 = 2.5); but otherwise, demographics did not differ between genotypes (Table 1) . Because of racial differences in the prevalence of the A-308G polymorphism, we specifically examined white Americans, but we then repeated some analyses in all subjects regardless of selfreported race.
Tumor Necrosis Factor > Polymorphism is Associated With Labile Anger Development
Among European American subjects, labile anger increased more ( Fig. 1 ) in those with the A allele (F 5,66.4 = 2.5; P G 0.05) compared with those with the G/G genotype. There was no significant relationship between race and the development of labile anger (F 5,79.4 = 1.9; P = 0.09), and the genotype relationship with labile anger continued to be evident when including African Americans in the analysis (F 5,70.2 = 3.1; P G 0.05).
Tumor Necrosis Factor > Polymorphism is Not Associated With Other Mental Health Problems
Genotype was not associated with the development of irritability (P = 0.45) or assault (P = 0.72). In addition, although sleep quality (as assessed with the Pittsburgh Sleep Quality Inventory) worsened over time (F 5,70.3 = 2.8; P G 0.05), there was no relationship between genotype and the worsening sleep quality (F 5,70.3 = 1.4; P = 0.24). Time until development of MDD during interferon alfa therapy, which occurred in 27 subjects, was also not associated with the TNF-> genotype in whites (W 1 2 = 0.4; P = 0.53) or in all subjects combined (W 1 2 = 0.0; P = 0.99). Beck Depression Inventory score increased over time during interferon alfa therapy (F 5,87.4 = 6.2; P G 0.001), but this was not associated with genotype (F 5,81.2 = 1.2; P = 0.31). There was not any main effect of genotype on BDI (F 1,87.2 = 0.3; P = 0.63). When including African Americans in the analysis of BDI, there was a trend for those with the A allele to develop more depression symptoms (F 5,87.4 = 2.1; P G 0.08), but this was not significant.
Exploratory Analysis of TNF-> Polymorphism and Individual BDI Items
Ten individual BDI items worsened during interferon alfa treatmentVitem nos. 3, 7, 10, 11, 12, 14, 15, 17, 18, and There were no statistically significant (ns) differences in demographics between subjects who developed MDD and those who did not. The A allele was more prevalent in self-identified African Americans. 10 (crying), 11 (agitation), and 17 (irritability). Genotype was associated with a combined measure of fatigue and loss of energy (F 5,78.0 = 2.9; P G 0.05; Fig. 2A ). An association between genotype and worsening of crying/agitation/irritability was not statistically significant (F 5,86.8 = 1.4; P = 0.22; Fig. 2B ).
Association of TNF-> Polymorphism and Labile Anger is Not Mediated by Fatigue
The composite measure of fatigue/low energy was slightly correlated with labile anger (R = 0.17; F = 10.3; P G 0.001), and both were associated with the TNF-> polymorphism. When including the composite fatigue/energy measure as a time-varying covariate in the repeated measure longitudinal mixed-effect analysis, the A allele continued to predict worsening of labile anger during interferon alfa treatment (F 5,70.4 = 2.9; P G 0.05), arguing against mediation by fatigue.
Peripheral TNF-> Levels and Psychiatric Symptoms
Monthly TNF-> levels (Fig. 3 ) increased during interferon alfa treatment (F 4,54.9 = 4.4; P G 0.005). However, this was not associated with genotype (F 4,45.8 = 0.4; P = 0.78). Those who developed MDD trended toward greater TNF-> levels during treatment (F 4.47.8 = 2.3; P = 0.08). We next compared TNF-> levels in those with labile anger scores greater than 5 anytime during treatment (the median split point) with those scoring 5 or lower (Fig. 3) . The difference in levels was not significant (F 1,75.5 = 1.1; P = 0.30).
Including peripheral TNF-> levels as a covariate, we repeated the repeated-measure mixed-effect analysis of genotype on labile anger. The association between the A allele and increased labile anger remained (F 4,44.5 = 15.7; P G 0.001). It is 
Serotonin Transporter Promoter Length Polymorphism is Not Associated With Labile Anger Development
Because we have previously reported a relationship between the 5-HTTLPR genotype and MDD during interferon alfa therapy in an overlapping set of these patients, 28 we assessed an association between 5-HTTLPR and the development of labile anger. No relationship was found (F 10,52.3 = 0.8; P = 0.59).
DISCUSSION
The A allele in the j308 promoter region of TNF-> was specifically associated with worsening labile anger during interferon alfa treatment. Labile anger was based on questions in the Anger Irritability and Assault Questionnaire about having minimal control over switches in temper; feeling normally OK but then suddenly feeling angry or furious with the urge to yell; or feeling so mad as to experience shaking, a pounding heart, and/or the urge to hit something. 77 Of note, the A allele was specifically associated with labile anger and not with irritability or increases in assault behaviors (either verbal or physical). We also did not find any association between the TNF-> polymorphism and the development of categorical MDD or the worsening BDI, consistent with most prior studies. 62Y65 Several groups have independently described increases in hostility-related complaints in patients receiving interferon alfa treatment, 13Y20 something very disruptive for patients. 17 This phenomenon occurs whether depression develops or not 22 and is orthogonally distinct from increased depression on the Symptom Checklist 90. 23 Aggression and depression are under genetic influence in childhood twin studies, albeit via potentially distinct pathways. 79 In addition, 5-HTTLPR was associated with risk for MDD during interferon alfa treatment 27, 28 but not risk for labile anger. There may be a relationship between elevated peripheral interleukin 6 levels and MDD during interferon alfa therapy, 67, 80 despite no relationship between TNF-> levels and MDD. This is consistent with reports of elevated systemic interleukin 6 but not TNF-> in Bidiopathic[ MDD. 81 It is entirely speculative as to what this labile anger syndrome represents. BAnger attacks[ could be related to a depression subtype, 9 impulsive aggression, 10 mixed mood disorder, 70, 82 or an entirely distinct syndrome. Consistent with a mixed mood disorder hypothesis, mood dysregulation may be related to risk for bipolar disorder 83Y89 ; bipolar disorder and elevated TNF-> levels both may predict worse response to classic antidepressants 90, 91 ; and elevated TNF-> levels may occur in bipolar disorder. 92 Inconsistent with a mixed mood disorder hypothesis, we very rarely observed grandiosity, decreased sleep requirements, or increased goal-directed activities during interferon alfa treatment. Future work will be required to further delineate this labile anger Bsyndrome.[ An important limitation of this study is that our assessment of labile anger was limited to this single self-report questionnaire, and thus, the findings should be considered preliminary.
Anger during depression has been previously examined in genetic association analyses, with possible associations with CREB1, 93 ABCG1 transporter, 94 tryptophan hydroxylase, 95 monoamine oxidase A, 11 and catecholamine-O-methyl transferase. 96 A limitation to this study is that we also did not examine these genes or several other polymorphisms that are upstream from the TNF-> transcription start site (eg, positions j863, j376, j244, and j238). Future work will be required to more fully examine the role of genetic variation across the TNF-> gene and other candidate genes in labile anger.
We did examine whether worsening fatigue mediates the increased labile anger. Fatigue and malaise are well-known symptoms of interferon alfa treatment, 23, 97 and TNF-> has been associated with malaise in animal models. 98 Although TNF-> genotype was associated with increased fatigue, no mediation was found. Thus, the A allele may increase sensitivity to both fatigue and labile anger, albeit independently.
In addition, circulating levels of TNF-> were associated with neither psychiatric symptoms nor genotype. This is inconsistent with higher plasma TNF-> levels being associated with the A allele during inflammation 46Y48 and increased depressive symptoms correlating with lymphocyte production of TNF->. 99 Thus, our lack of associations with circulating TNF-> levels should be interpreted with caution. Nonetheless, the A-308G genotype has been associated with cognitive dysfunction in elderly subjects despite no association between genotype and peripheral TNF-> levels, 58 similar to our study. It is possible that central TNF-> may be of more relevance to psychiatric symptoms.
Tumor necrosis factor > levels in the brain can be influenced by stress or peripheral inflammation 35, 36, 38 and peripheral cytokines. 39 Similarly, interferon alfa decreases cell proliferation in the hippocampus by induction of local cytokines. 100 Therefore, it is plausible that the A-308G polymorphism could particularly influence localized central nervous system expression of TNF-> during interferon alfa treatment. Consistent with this speculation, the A-308G polymorphism may affect the binding of some transcriptional regulators but not others. 101Y105 Enhanced production of quinolinic acid may mediate some psychiatric effects of interferon alfa, 106 and elevated central TNF-> could be influential on this pathway. 40 In addition, increased central nervous system TNF-> can increase norepinephrine and serotonin turnover, 107 possibly mediated by its effect on c-Jun-Nterminal kinase. 108 As TNF-> can be induced in the limbic system, any of these central TNF-> influences could be a plausible mechanism leading to labile anger. Nonetheless, the pathway by FIGURE 3 . Systemic TNF-> levels (mean [SE]) increased during treatment. In subjects with labile anger scores greater than 5 at any time during treatment, this elevation was not significantly higher from those whose scores remained 5 or less.
which the A allele in the TNF-> promoter region specifically leads to enhanced labile anger requires future investigation.
In summary, the risk for inflammation-related labile anger may be enhanced in subjects with the A allele in the promoter region for TNF->. However, it should be reiterated that this study was specifically performed in patients undergoing therapy with interferon alfa. Whether TNF-> is associated with labile anger in other clinical situations requires examination. A strength of the interferon alfa paradigm is the ability to prospectively assess the development of symptoms; however, the limitation is the lack of generalization to other Bstressful[ or inflammatory scenarios. In addition, although hypothesis driven, these analyses had no correction for multiple testing and require replication. Regardless, the results indicate that genetic variation upstream from TNF-> may influence labile anger during a state of heightened inflammation without concomitantly influencing risk for depression.
